FDA approves ISEMBYLD, first muscle-targeted SMA therapy
Scholar Rock’s ISEMBYLD received FDA approval as the first muscle-targeted therapy for SMA, and the U.S. launch is underway with planned global expansion.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.